Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Inventory (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Inventory for 10 consecutive years, with $34.9 million as the latest value for Q1 2026.

  • For Q1 2026, Inventory rose 649.31% year-over-year to $34.9 million; the TTM value through Mar 2026 reached $34.9 million, up 649.31%, while the annual FY2025 figure was $32.8 million, 8849.18% up from the prior year.
  • Inventory hit $34.9 million in Q1 2026 for Syndax Pharmaceuticals, up from $32.8 million in the prior quarter.
  • Across five years, Inventory topped out at $34.9 million in Q1 2026 and bottomed at $366000.0 in Q4 2024.
  • Average Inventory over 3 years is $19.2 million, with a median of $21.3 million recorded in 2025.
  • Year-over-year, Inventory skyrocketed 8849.18% in 2025 and then skyrocketed 649.31% in 2026.
  • Syndax Pharmaceuticals' Inventory stood at $366000.0 in 2024, then surged by 8849.18% to $32.8 million in 2025, then rose by 6.7% to $34.9 million in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $34.9 million, $32.8 million, and $25.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.